• 1. Dual SNAr reaction in activated ortho-halonitrobenzene: direct synthesis of substituted 1,2,3,4-tetrahydroquinoxalines, 2,3-dihydro-1,4-benzoxazines, and 1,4-benzodioxines
  Mahesh S. Deshmukh,Biswajit Das,Nidhi Jain RSC Adv. 2013 3 22389
• 2. 911. The synthesis of some 6-substituted 1,2,3,4-tetrahydroquinoxalines
  P. Clarke,A. Moorhouse J. Chem. Soc. 1963 4763

• Solvents and Organic Chemicals Organic Compounds Organic 1,3-dipolar compounds Allyl-type 1,3-dipolar organic compounds C-nitro compounds
• Solvents and Organic Chemicals Organic Compounds Organic 1,3-dipolar compounds Allyl-type 1,3-dipolar organic compounds Organic nitro compounds C-nitro compounds

Introduction to 6-Nitro-1,2,3,4-tetrahydroquinoxaline (CAS No. 41959-35-7)

6-Nitro-1,2,3,4-tetrahydroquinoxaline, identified by its Chemical Abstracts Service (CAS) number 41959-35-7, is a significant compound in the realm of organic chemistry and pharmaceutical research. This heterocyclic aromatic amine has garnered attention due to its versatile structural framework and potential applications in medicinal chemistry. The nitro and tetrahydroquinoxaline moieties contribute to its unique reactivity, making it a valuable intermediate in synthesizing biologically active molecules.

The nitro group attached to the quinoxaline core plays a pivotal role in modulating the electronic properties of the molecule. This substitution enhances its potential as a precursor in the development of pharmacophores targeting various therapeutic pathways. Recent studies have highlighted the utility of nitro-substituted quinoxalines in designing compounds with antimicrobial and anti-inflammatory properties. The tetrahydroquinoxaline scaffold, characterized by its saturated ring system, introduces conformational flexibility, which is often exploited to improve drug-like characteristics such as solubility and metabolic stability.

In the context of modern drug discovery, 6-Nitro-1,2,3,4-tetrahydroquinoxaline has been explored as a key building block in the synthesis of novel therapeutic agents. Its structural motif is reminiscent of several known bioactive compounds, suggesting that derivatives of this compound may exhibit similar pharmacological effects. For instance, modifications at the nitro position or the tetrahydroquinoxaline ring have been investigated for their impact on binding affinity to biological targets. Such structural diversifications are crucial for optimizing lead compounds and enhancing their efficacy.

Recent advancements in computational chemistry have enabled more efficient virtual screening of molecules like 6-Nitro-1,2,3,4-tetrahydroquinoxaline. By leveraging molecular docking simulations and quantum mechanical calculations, researchers can predict potential interactions between this compound and biological receptors. These computational approaches have accelerated the identification of promising candidates for further experimental validation. Moreover, the integration of machine learning algorithms has allowed for the rapid design of optimized derivatives with improved pharmacokinetic profiles.

The synthesis of 6-Nitro-1,2,3,4-tetrahydroquinoxaline typically involves multi-step organic transformations starting from readily available precursors. The introduction of the nitro group is often achieved through nitration reactions under controlled conditions to prevent over-substitution or decomposition. The tetrahydroquinoxaline ring can be constructed via cyclization reactions or hydrogenation processes depending on the synthetic route chosen. These methodologies highlight the compound's synthetic accessibility and its suitability for large-scale production if required.

From a medicinal chemistry perspective, 6-Nitro-1,2,3,4-tetrahydroquinoxaline has been implicated in several research pipelines aimed at addressing unmet medical needs. Its scaffold is structurally analogous to molecules known for their antiviral and anticancer activities. For example, derivatives bearing similar nitrogen-rich heterocycles have shown promise in preclinical studies as inhibitors of kinases or other enzymes involved in disease progression. The nitro group further adds a layer of functional tunability that can be exploited to fine-tune bioactivity.

The pharmacological potential of 6-Nitro-1,2,3,4-tetrahydroquinoxaline extends beyond traditional therapeutic areas. Emerging research suggests its relevance in neurodegenerative disorders due to its ability to modulate neurotransmitter systems. The compound's ability to cross the blood-brain barrier makes it an attractive candidate for central nervous system (CNS) drug development. Additionally, its interaction with redox-sensitive proteins implies possible applications in oxidative stress-related diseases such as Alzheimer's and Parkinson's.

In conclusion,6-Nitro-1,2,3,4-tetrahydroquinoxaline (CAS No. 41959-35-7) represents a fascinating compound with broad applicability in pharmaceutical research. Its unique structural features—combining a nitro group with a tetrahydroquinoxaline core—make it a versatile intermediate for designing novel bioactive molecules. Ongoing studies continue to uncover new synthetic pathways and pharmacological applications for this compound and its derivatives. As drug discovery technologies evolve further,6-Nitro-1,2,3,4-tetrahydroquinoxaline is poised to remain at the forefront of medicinal chemistry innovation.

• 5431-37-8(N,N''-bis(2-nitrophenyl)ethane-1,2-diamine)
• 66668-41-5(N1-Ethyl-4-nitrobenzene-1,2-diamine)
• 51138-16-0(N-(2-Aminoethyl)-2-nitroaniline)
• 28767-75-1(N1-(2,4-Dinitrophenyl)ethane-1,2-diamine)
• 130688-53-8(1,2,3,4-tetrahydro-1-methyl-6-nitro-Quinoxaline)
• 16773-16-3(1,2-Ethanediamine,N1-(2,4-dinitrophenyl)-N2-phenyl-)
• 29549-98-2(1,2-Ethanediamine,N,N'-bis(2,4-dinitrophenyl)- (9CI))
• 158006-54-3(TETRAHYDRO-6-NITROQUINOXALINEHYDROCHLORIDE)
• 41959-36-8(Quinoxaline, 1,2,3,4-tetrahydro-5-nitro- (9CI))
• 71319-72-7(N1-(3-Nitrophenyl)ethane-1,2-diamine)